CliffBio
small molecule

SANCUSO

GRANISETRON

Loss of exclusivity—loss of exclusivity
CompanyCumberland →See this company's full patent-cliff portfolio

Drug detail

Brand nameSANCUSO
Active ingredientGRANISETRON
Strength3.1MG/24HR
Dosage formFILM, EXTENDED RELEASE
RouteTRANSDERMAL
ModalitySmall molecule
FDA approvalSeptember 2008
Marketing statusRX

More from Cumberland

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.